181 related articles for article (PubMed ID: 32684169)
1. Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study.
Courcelle R; Gaudry S; Serck N; Blonz G; Lascarrou JB; Grimaldi D;
Crit Care; 2020 Jul; 24(1):446. PubMed ID: 32684169
[No Abstract] [Full Text] [Related]
2. Neutrophil Elastase Inhibitors: A potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?
Mohamed MMA; El-Shimy IA; Hadi MA
Crit Care; 2020 Jun; 24(1):311. PubMed ID: 32513225
[No Abstract] [Full Text] [Related]
3. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?
Bendjelid K; Giraud R; Von Düring S
Anaesth Crit Care Pain Med; 2020 Aug; 39(4):451-452. PubMed ID: 32653550
[No Abstract] [Full Text] [Related]
4. Shortage of sedatives and neuromuscular blockers during COVID-19 pandemic: The result of an overstocking procedure in French hospitals?
Montmeat D; Gard C; Raux M; Constantin JM; Tilleul P
Anaesth Crit Care Pain Med; 2020 Oct; 39(5):585-586. PubMed ID: 32654910
[No Abstract] [Full Text] [Related]
5. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Cadegiani FA
Am J Physiol Endocrinol Metab; 2020 May; 318(5):E587-E588. PubMed ID: 32297520
[No Abstract] [Full Text] [Related]
6. Impact of initial respiratory compliance in ventilated patients with acute respiratory distress syndrome related to COVID-19.
Laverdure F; Delaporte A; Bouteau A; Genty T; Decailliot F; Stéphan F
Crit Care; 2020 Jul; 24(1):412. PubMed ID: 32646470
[No Abstract] [Full Text] [Related]
7. Fibrinolytic therapy in patients with COVID-19 and acute respiratory distress syndrome: Is this a feasible approach?
Savioli F; Rocha L; Góis A; Nakano LC
J Trauma Acute Care Surg; 2020 Dec; 89(6):e187-e188. PubMed ID: 32868539
[No Abstract] [Full Text] [Related]
8. Prone positioning under VV-ECMO in SARS-CoV-2-induced acute respiratory distress syndrome.
Garcia B; Cousin N; Bourel C; Jourdain M; Poissy J; Duburcq T;
Crit Care; 2020 Jul; 24(1):428. PubMed ID: 32665007
[No Abstract] [Full Text] [Related]
9. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Caocci G; La Nasa G
Ann Hematol; 2020 Jul; 99(7):1675-1676. PubMed ID: 32405693
[No Abstract] [Full Text] [Related]
10. Physiological Changes During Prone Positioning in COVID-19 Acute Respiratory Distress Syndrome.
Lee RM; Tan GP; Puah SH; Ling LM; Choy CY; Chotirmall SH; Abisheganaden J; See JJ; Tan HL; Wong YL
Ann Acad Med Singap; 2020 Jul; 49(7):509-513. PubMed ID: 33000116
[No Abstract] [Full Text] [Related]
11. Considerations for Statin Therapy in Patients with COVID-19.
Dashti-Khavidaki S; Khalili H
Pharmacotherapy; 2020 May; 40(5):484-486. PubMed ID: 32267560
[No Abstract] [Full Text] [Related]
12. Vitamin C levels in patients with SARS-CoV-2-associated acute respiratory distress syndrome.
Chiscano-Camón L; Ruiz-Rodriguez JC; Ruiz-Sanmartin A; Roca O; Ferrer R
Crit Care; 2020 Aug; 24(1):522. PubMed ID: 32847620
[No Abstract] [Full Text] [Related]
13. Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection.
Soto M; diZerega G; Rodgers KE
J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972018. PubMed ID: 33169644
[TBL] [Abstract][Full Text] [Related]
14. Positive end-expiratory pressure titration in COVID-19 acute respiratory failure: electrical impedance tomography vs. PEEP/FiO
Sella N; Zarantonello F; Andreatta G; Gagliardi V; Boscolo A; Navalesi P
Crit Care; 2020 Sep; 24(1):540. PubMed ID: 32873337
[No Abstract] [Full Text] [Related]
15. Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease.
Taboada M; Caruezo V; Naveira A; Atanassoff PG
J Clin Anesth; 2020 Nov; 66():109926. PubMed ID: 32474331
[No Abstract] [Full Text] [Related]
16. Lung Recruitability in COVID-19-associated Acute Respiratory Distress Syndrome: A Single-Center Observational Study.
Pan C; Chen L; Lu C; Zhang W; Xia JA; Sklar MC; Du B; Brochard L; Qiu H
Am J Respir Crit Care Med; 2020 May; 201(10):1294-1297. PubMed ID: 32200645
[No Abstract] [Full Text] [Related]
17. Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.
Mohammed A; F K Alghetaa H; Miranda K; Wilson K; P Singh N; Cai G; Putluri N; Nagarkatti P; Nagarkatti M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872332
[TBL] [Abstract][Full Text] [Related]
18. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Kloc M; Ghobrial RM
Mult Scler Relat Disord; 2020 Oct; 45():102437. PubMed ID: 32763844
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.
Smetana K; Rosel D; BrÁbek J
In Vivo; 2020; 34(5):3027-3028. PubMed ID: 32871847
[TBL] [Abstract][Full Text] [Related]
20. Usefulness and safety of a dedicated team to prone patients with severe ARDS due to COVID-19.
Kimmoun A; Levy B; Chenuel B;
Crit Care; 2020 Aug; 24(1):509. PubMed ID: 32811555
[No Abstract] [Full Text] [Related]
[Next] [New Search]
